Literature DB >> 8713080

Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.

S Orlowski1, L M Mir, J Belehradek, M Garrigos.   

Abstract

P-glycoprotein (P-gp) is a membranous ATPase responsible for the multidrug resistance (MDR) phenotype. Using membrane vesicles prepared from the highly resistant cell line DC-3F/ADX we studied the influence of P-gp ATPase activity of four progesterone derivatives which specifically bind to P-gp and reverse MDR. Progesterone and desoxycorticosterone stimulate P-gp ATPase activity with, respectively, apparent concentrations giving half-maximal activation of 20-25 microM and 40-50 microM, and activation factors of 2.3 (at 100 microM progesterone) and 1.8 (at 170 microM desoxycorticosterone). Hydrocortisone above 100 microM stimulates P-gp ATPase activity while corticosterone has no apparent stimulating effect. Our data are consistent with the location of the binding sites for the progesterone derivatives on the P-gp membranous domain. The effects of these steroids on verapamil-stimulated P-gp ATPase activity support a non-competitive mechanism, i.e. the binding sites for verapamil and steroids are mutually non-exclusive for P-gp ATPase modulation. A similar non-competitive inhibition of progesterone-stimulated P-gp ATPase activity by desoxycorticosterone or by corticosterone leads to the conclusion that these steroids, although sharing related structures, have distinct modulating sites on P-gp. As expected from their mutually non-exclusive interactions on P-gp, progesterone and verapamil when mixed induce a synergistic modulation of P-gp ATPase activity. Since drug transport by P-gp is believed to be coupled to its ATPase activity, a corresponding synergistic effect of these two modulators for the inhibition of P-gp-mediated drug resistance can be expected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713080      PMCID: PMC1217517          DOI: 10.1042/bj3170515

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  55 in total

Review 1.  Pharmacology of drugs that alter multidrug resistance in cancer.

Authors:  J M Ford; W N Hait
Journal:  Pharmacol Rev       Date:  1990-09       Impact factor: 25.468

2.  Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells.

Authors:  Y Raviv; H B Pollard; E P Bruggemann; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

3.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.

Authors:  K Yusa; T Tsuruo
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

4.  Reversal of multidrug resistance by lipophilic drugs.

Authors:  E Hofsli; J Nissen-Meyer
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

5.  Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance.

Authors:  M Azzaria; E Schurr; P Gros
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

Review 6.  What is synergy?

Authors:  M C Berenbaum
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

7.  Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells.

Authors:  I Tamai; A R Safa
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

8.  Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts.

Authors:  X D Qian; W T Beck
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

9.  Differential transport properties of two mdr gene products are distinguished by progesterone.

Authors:  C P Yang; D Cohen; L M Greenberger; S I Hsu; S B Horwitz
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

10.  How do volatile anesthetics inhibit Ca(2+)-ATPases?

Authors:  M M Lopez; D Kosk-Kosicka
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  32 in total

1.  Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.

Authors:  Anis Bessadok; Elisabeth Garcia; Hélène Jacquet; Solenne Martin; Alexia Garrigues; Nicolas Loiseau; François André; Stéphane Orlowski; Michel Vivaudou
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

2.  Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Authors:  Samy A F Morad; Traci S Davis; Matthew R MacDougall; Su-Fern Tan; David J Feith; Dhimant H Desai; Shantu G Amin; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2017-02-09       Impact factor: 5.858

3.  The detergent-soluble maltose transporter is activated by maltose binding protein and verapamil.

Authors:  R Reich-Slotky; C Panagiotidis; M Reyes; H A Shuman
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

4.  Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein.

Authors:  Bhargav A Patel; Biebele Abel; Anna Maria Barbuti; Uday Kiran Velagapudi; Zhe-Sheng Chen; Suresh V Ambudkar; Tanaji T Talele
Journal:  J Med Chem       Date:  2018-01-23       Impact factor: 7.446

5.  In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells.

Authors:  Fadwa Chaabane; Mounira Krifa; Eva Matera; Amira Loussaeif; Marie-Geneviève Dijoux-Franca; Kamel Ghedira; Charles Dumontet; Leila Chekir-Ghedira
Journal:  Tumour Biol       Date:  2014-06-06

6.  Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein.

Authors:  Kaitlyn V Ledwitch; Morgan E Gibbs; Robert W Barnes; Arthur G Roberts
Journal:  Biochem Pharmacol       Date:  2016-08-13       Impact factor: 5.858

7.  Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1).

Authors:  Satyakam Singh; Nagarajan Rajendra Prasad; Khyati Kapoor; Eduardo E Chufan; Bhargav A Patel; Suresh V Ambudkar; Tanaji T Talele
Journal:  Chembiochem       Date:  2013-11-29       Impact factor: 3.164

8.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein.

Authors:  G Conseil; H Baubichon-Cortay; G Dayan; J M Jault; D Barron; A Di Pietro
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

10.  P-glycoprotein in proteoliposomes with low residual detergent: the effects of cholesterol.

Authors:  Karsten Bucher; Sara Belli; Heidi Wunderli-Allenspach; Stefanie D Krämer
Journal:  Pharm Res       Date:  2007-05-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.